DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03885297

Completed

3mg Liraglutide for Overweight or Obesity

Investigation of the Metabolic Effects of 3mg Liraglutide on Patients With Overweight or Obesity

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

43

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Body weight, absolute change (kg)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03885297
Org study IDGD410218
Secondary ID250896IRAS ID number

Timeline

Milestones

Study start2019-01-18actual
Study first posted2019-03-21actual
Primary completion2020-12-18actual
Study completion2020-12-18actual
Last update posted2024-06-18actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersAccepted
Sampling methodProbability sample

Study population text

Investigators don't anticipate any specific difficulties with recruitment for this study as overweight and obesity are very common conditions, and there are very few licensed medical options offering substantial weight loss. Liraglutide is one of them. Additionally, investigators don't see any specific difficulties in managing this study as it will be " part and parcel" of our patients' routine clinical visits. Liraglutide is going to be offered to our patients as per clinical need and the decision to treat them with liraglutide is going to be made before their potential participation in our study. Patients therefore are not going to be receiving treatment because of their participation in our study.

Inclusion criteria

•Adult participants [age ≥18 y.o without upper age limit (to the discretion of the investigators)].
•Body mass index (BMI) ≥ 30 kg/m2 without coexisting comorbidities or BMI ≥27Kg/m2 with comorbidities like hypertension, hyperlipidaemia, prediabetes or obstructive sleep apnoea.
•Willing to comply with study requirements and able to give informed consent.

Exclusion criteria

•Type 1 or Type 2 diabetes mellitus
•History of chronic or acute pancreatitis
•Known active hepatitis or active liver disease
•Symptomatic gallstones or kidney stones, acute cholecystitis or history of duodenal inflammatory diseases including Crohn's Disease and Celiac Disease
•Persistent anaemia, defined as haemoglobin<10 g/dl
•Chronic or acute renal impairment (eGFR <30 ml/min/1.73m2)
•Active systemic infection (sepsis)
•Active malignancy within the last 5 years, including any form of thyroid cancer (including sporadic or familial medullary thyroid cancer) or personal, or family history of Multiple Endocrine Neoplasia type 2.
•Active illicit substance abuse or alcoholism
•Current pregnancy or breastfeeding at screening or 6 months previously
•Donated blood during the preceding 3 months or intention to do so before the end of the study.
•Any other mental or physical condition which, in the opinion of the Investigator, makes the subject a poor candidate for clinical trial participation.

Endpoints (11)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
4
Other (unclassified)
4
Weight & body composition
2
Glycemic / diabetes
1

Weight & body composition

2 endpoints
Primary/protocol endpoint

Weight changes related to treatment

Time frame:6 months

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Changes in fat and lean mass while on treatment

Time frame:6 months

Total fat mass

percent change from baseline, improvement

componentsTotal fat mass, Lean mass

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Changes in glucose and insulin from baseline.

Time frame:6 months

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Cardiometabolic biomarkers

4 endpoints
Secondary/protocol endpoint

Changes in an untargeted study of lipid metabolites (C18 reversed phase LCMS) while on treatment

Time frame:6 months

change from baseline, descriptive

Secondary/protocol endpoint

Changes in systolic blood pressure.

Time frame:6 months

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Changes diastolic blood pressure.

Time frame:6 months

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Secondary/protocol endpoint

Changes in heart rate.

Time frame:6 months

Heart rate, change

change from baseline, improvement

Other (unclassified)

4 endpoints
Secondary/protocol endpoint/low confidence

Changes in an untargeted study of water-soluble metabolites (HILIC LCMS) while on treatment

Time frame:6 months

descriptive

Secondary/protocol endpoint/low confidence

Changes in the expression of miRNA-155 while on treatment.

Time frame:6 months

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Changes in the expression of miRNA-221 while on treatment.

Time frame:6 months

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Changes in the expression of miRNA-222 while on treatment.

Time frame:6 months

change from baseline, descriptive

Publications (4)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.